Given previous research, the usage of ACEis and ARBs may have potential benefit in preventing COVID-19-triggered organ damage, given the drug's ability to upregulate ang-(1-7) and deplete angiopoietin-2 (ang-2). Here, ANGPT2 is linked to COVID-19.